Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion description "[The type I EGF receptor (EGFR or ErbB1) and insulin-like growth factor-binding protein-3 (IGFBP-3) are highly expressed in triple-negative breast cancer (TNBC), a particularly aggressive disease that cannot be treated with conventional therapies targeting the estrogen or progesterone receptors (ER and PR), or HER2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion evidence source_evidence_literature NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion SIO_000772 24337110 NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion wasDerivedFrom befree-20150227 NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion wasGeneratedBy ECO_0000203 NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- befree-20150227 importedOn "2015-02-27" NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.